Teva Pharmaceutical Industries Ltd.’s (TEVA:US) early progress in shifting daily Copaxone takers to a new formulation has persuaded some analysts the drugmaker may succeed in converting as many as half of its multiple sclerosis patients. Teva converted 8.7 percent of total 20-milligram Copaxone prescriptions to its 40-milligram injections for the week ending Feb. 28, according to Bloomberg Industries. Leerink Swann & Co. and Cowen & Co. analysts said the results mean the world’s largest maker of generic drugs may deliver on its plan to bring round 30 percent to 50 percent of patients to the three-times-weekly version.
Help employers find you! Check out all the jobs and post your resume
